Rethinking health with Fatima GrigoriouView Episode >
Meet the guest and the host
The guest of this edition of the podcast is Prof. Richard Sullivan, Director of the Institute of Cancer Policy and Co-Director of the Centre for Conflict & Health Research at King’s College London
Dr. Marius, President and Co-founder of the Centre for Innovation in Medicine is the host of the ReThink Health podcast. He is a pioneer in the field of personalised medicine in Romania and Central Eastern Europe and is involved in multiple pan-European innovative healthcare projects and initiatives.
Meet The Team
Public Health Engineer and Science Communicator at the Centre for Innovation in Medicine. BSc and MSc at Politehnica University of Bucharest in Computer Systems in Medicine. Passionate about health policies, behavioural sciences and personalised medicine. Her fields of research include health literacy and human Digital Twins.
Medical Lead and Science Communicator at the Centre for Innovation in Medicine. MD in General Medicine and currently specialising in Medical Genetics at Carol Davila University of Bucharest. Passionate about genomics, personalised prevention, health systems transformation. Her research fields include precision oncology, public health and health literacy. She is also a member of the Young Forum Gastein Alumni Community and EIT Alumni Community.
Senior psychiatry resident doctor, currently undergoing PhD studies within the field of healthcare communication. She holds a Master of Public Health which enabled her to purse her interests in public mental health and healthcare communication. She joined the Centre for Innovation in Medicine in 2020 as a science communicator and policy researcher, aiming to contribute to bridging the health gap by advocating for early adoption of and access to medical innovations.
PhD researcher at the Department of PharmacoTherapy, University of Groningen. MSc at King’s College London and University College London in Pharmacology and Molecular Genetics. His research focuses on investigating pharmacogenetic variants in neurotransmitter pathways and conducting economic evaluations of genetic testing.